Article Abstract

Improving outcomes for brain metastases in EGFR mutated NSCLC

Authors: Jennifer W. Carlisle, Suresh S. Ramalingam


Tyrosine kinase inhibitors (TKIs) of activating epidermal growth factor receptor (EGFR) mutations have revolutionized the care of patients with advanced non-small cell lung cancer (NSCLC) who harbor a targetable EGFR mutation. Compared to platinum doublet chemotherapy, median overall survival (OS) has improved from a historical 8–12 months with chemotherapy alone (1) to 26 months with first generation EGFR TKIs gefitinib and erlotinib (2).